Search

Your search keyword '"Allergan PLC -- Product development"' showing total 161 results
Start Over Descriptor "Allergan PLC -- Product development"
161 results on '"Allergan PLC -- Product development"'

151. Allergan and Richter declare positive results for Phase III clinical trials on efficacy and safety of ulipristal acetate in women with uterine fibroids

Subjects
Allergan PLC -- Product development, Clinical trials, Uterine fibroids, Pharmaceutical industry -- Product development, Business
Abstract

M2 EQUITYBITES-May 9, 2016-Allergan and Richter declare positive results for Phase III clinical trials on efficacy and safety of ulipristal acetate in women with uterine fibroids. (C)2016 M2 COMMUNICATIONS http://www.m2.com [...]

Published
2016

152. Memory Impairment Global Clinical Trials Review, H2, 2015 - Key Vendors are Allergan Plc, Pfizer Inc. & Allied Clinical Management GmbH - Research and Markets

Subjects
Allergan PLC -- Product development, Pfizer Inc. -- Product development, Memory, Pharmaceutical industry -- Product development, Biotechnology industry, Biological sciences, Business
Abstract

2016 MAR 21 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- Research and Markets (http://www.researchandmarkets.com/research/8dl656/memory_impairment) has announced the addition of the 'Memory Impairment Global Clinical [...]

Published
2016

153. Essential Tremor Global Clinical Trials Review, H2, 2015 - Key Players are Allergan Plc, Sage Therapeutics & Pfizer Inc. - Research and Markets

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Tremor, Biotechnology industry, Biological sciences, Business
Abstract

2016 MAR 21 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- Research and Markets (http://www.researchandmarkets.com/research/6bkpnz/essential_tremor) has announced the addition of the 'Essential Tremor Global Clinical [...]

Published
2016

154. Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015 - Key Vendors: Allergan Plc, ANI Pharmaceuticals, Inc. & Palatin Technologies, Inc. - Research and Markets

Subjects
Allergan PLC -- Product development, ANI Pharmaceuticals Inc. -- Product development, Palatin Technologies Inc. -- Product development, Sexual disorders, Pharmaceutical industry -- Product development, Biological products industry -- Product development, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2016 FEB 1 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Research and Markets (http://www.researchandmarkets.com/research/64h2nk/female_sexual) has announced the addition of the 'Female Sexual Dysfunction Global [...]

Published
2016

155. Ironwood Pharmaceuticals Announces Initiation of Phase II Trial of Linaclotide in Adult Patients with Opioid-Induced Constipation

Subjects
Allergan PLC -- Product development, Clinical trials, Irritable bowel syndrome -- Drug therapy, Constipation -- Drug therapy, Pharmaceutical industry -- Product development, Business, Business, international, Linzess (Medication) -- Product development
Abstract

CAMBRIDGE, Mass. -- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today the initiation of a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation (OIC). [...]

Published
2014

156. FDA Approves Actavis' Abbreviated NDA for Exalgo Tablets - Shares Firm Late

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Mallinckrodt Inc. -- Product development, Medical test kit industry -- Product development, Medical equipment and supplies industry -- Product development, Drug approval, Pharmaceutical industry -- Product development, Business, Exalgo (Medication) -- Product development
Abstract

Boston, May 13, 2014 (MidnightTrader via COMTEX) -- Actavis plc (ACT) has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a [...]

Published
2014

157. Allergan plc (NYSE: AGN) - Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration -- 11/10/2019

Subjects
Allergan PLC -- Product development, Clinical trials -- Physiological aspects, Macular degeneration -- Physiological aspects, Ranibizumab -- Physiological aspects, Medical research -- Physiological aspects, Pharmaceutical industry -- Product development -- Physiological aspects, Ophthalmology, Business, international
Abstract

DUBLIN, Oct. 11, 2019/PRNewswire/--Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners (SIX: MOLN), a clinical-stage biopharmaceutical company developing [...]

Published
2019

158. Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation

Subjects
Allergan PLC -- Product development, Clinical trials, Constipation, Pharmaceutical industry -- Product development, Health, Linzess (Medication)
Abstract

2015 DEC 14 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced that the Phase II clinical trial of linaclotide [...]

Published
2015

161. Richter and Actavis Announce Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia

Subjects
Allergan PLC -- Product development, Diseases -- Relapse, Schizophrenia -- Care and treatment, Clinical trials, Pharmaceutical industry -- Product development, Health
Abstract

By a News Reporter-Staff News Editor at Clinical Trials Week -- Gedeon Richter Plc. and Actavis plc (NYSE: ACT) announced positive results from a Phase III trial evaluating the efficacy [...]

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results